The Incidence of Invasive Fungal Infections (IFI) in AML Patients Treated with a Hypomethylating Agent
The aim of our study was to selectively analyze newly diagnosed acute myeloid leukemia patients treated with a hypomethylating agent and establish their risk for developing invasive fungal infections (IFI). We stratified patients into concern for IFI (cIFI) versus no concern, and observed that patients of the male gender and those with underlying chronic obstructive pulmonary disease (COPD) are at higher risk for cIFI, which may prompt clinicians to consider anti-mold prophylaxis in this setting.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Michael Ozga, Ying Huang, James S. Blachly, Nicole R. Grieselhuber, Sarah Wall, Karilyn Larkin, Tamanna Haque, Alison R. Walker, Bhavana Bhatnagar, Gregory Behbehani, Sumithira Vasu, Joseph E. Maakaron, Mark Lustberg, Alice S. Mims Tags: Original Study Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Chronic Leukemia | Chronic Obstructive Pulmonary | Fungal Infections | Hematology | Leukemia | Lymphoma | Myeloma | Study